Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 236

Sort by

Sort Order Select

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis

Surbhi Sidana, MD, Surendra Dasari, PhD, Taxiarchis Kourelis, MD, Angela Dispenzieri, MD, David L Murray, MD PhD, Rebecca L. King, MD, Ellen D. McPhail, MD, Marina Ramirez-Alvarado, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2019) 134 (Supplement_1): 1770.

https://doi.org/10.1182/blood-2019-121714

Published: 2019

Journal Articles

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Michael Ozga, MD, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Patrick Elder, MS, Nita Williams, Naresh Bumma, MD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Rami Kahwash, MD, Ajay Vallakati, MD, Courtney Campbell, MD PhD, Samir Parikh, MD, Salem Almaani, MD, Jason Prosek, MD, Elyse Redder, PT, CLT-LANA, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 1833.

https://doi.org/10.1182/blood-2019-124206

Published: 2019

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, MD, Giampaolo Merlini, MD, Pieter Sonneveld, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1868.

https://doi.org/10.1182/blood-2019-126524

Published: 2019

Journal Articles

The UK Experience of Renal Transplantation in AL Amyloidosis

Oliver C Cohen, MB BS, BSc, FRCPath, Faye Sharpley, MBBChir, MA, MRCP, MSc, Julian Gillmore, Helen Lachmann, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Ana Martinez De Azcona Naharro, Marianna Fontana, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (Supplement_1): 2206.

https://doi.org/10.1182/blood-2019-128443

Published: 2019

Journal Articles

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, David Iberri, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Richard Lafayette, MD, Sally Arai, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1884.

https://doi.org/10.1182/blood-2019-124981

Published: 2019

Journal Articles

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Sally Arai, MD, Richard Lafayette, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1828.

https://doi.org/10.1182/blood-2019-122152

Published: 2019

Journal Articles

High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment

Anaïs Roeser, MD, Marine Bravetti, MD, Levi-Dan Azoulay, MD, Makoto Miyara, MD, Jean-François Emile, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Fleur Cohen-Aubart, MD PhD, Julien Haroche

Blood (2019) 134 (Supplement_1): 2324.

https://doi.org/10.1182/blood-2019-129984

Published: 2019

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Sneha Purvey, MD, Kenneth Seier, MS, Sean M. Devlin, PhD, Josel D Ruiz, MPH, Molly A. Maloy, MS, Gunjan L. Shah, MDMS, Hani Hassoun, MD, Sergio A. Giralt, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 4577.

https://doi.org/10.1182/blood-2019-129195

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Poornima Ramadas, MBBS, Ajay Tambe, MBBS, Mijung Lee, MD

Blood (2019) 134 (Supplement_1): 5463.

https://doi.org/10.1182/blood-2019-131577

Published: 2019

Journal Articles

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

So Yeon Kim, MD, Amanda Vest, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5502.

https://doi.org/10.1182/blood-2019-123890

Published: 2019

Journal Articles

Role of Echocardiography and Cardiac Biomarkers in Early Detection of Hematopoietic Stem Cell Transplantation Associated Cardiotoxicity

Ana Carolina Oliver, MD, Roberto Superchi, MD, Superchi Federico, MD, Canabal Matilde, MD, Jubin Silvana, Lic, Carolina Errecarte, MD, Caneiro Ada, MD, Silvia Pierri, MD, Sebastian Galeano, MD, Eloisa Riva, MD, Bello Laura, MD, Regis Gai, MD, Miller Andrew, MD, Pablo J. Muxi, MD, Ricardo Fabian Mosquera, MD

Blood (2019) 134 (Supplement_1): 5688.

https://doi.org/10.1182/blood-2019-127680

Published: 2019

Journal Articles

Vasculo-Behcet's Disease: Profile and Management - Single Center Experience

Mohammed Abdullah Alsheef, MD, Kamal Gazal, MD, Nahar Alenizi, MD, Khalid Qushmaq, MD, Mukhtar Alomar, PharmD, Ghaydaa Juma Kullab, MD, Abdul Rehman Z. Zaidi, MBBS

Blood (2019) 134 (Supplement_1): 4955.

https://doi.org/10.1182/blood-2019-130548

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

Thrombotic Thrombocytopenia Purpura Case Series in Skmc 2016-2017

Mohamed Abu Haleeqa, MBBS, Hanan Al Raeesi, MBBS, Fatima Alkaabi, MBBS

Blood (2019) 134 (Supplement_1): 4799.

https://doi.org/10.1182/blood-2019-126479

Published: 2019

NARROW

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

The UK Experience of Renal Transplantation in AL Amyloidosis

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

Role of Echocardiography and Cardiac Biomarkers in Early Detection of Hematopoietic Stem Cell Transplantation Associated Cardiotoxicity

Vasculo-Behcet's Disease: Profile and Management - Single Center Experience

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Thrombotic Thrombocytopenia Purpura Case Series in Skmc 2016-2017

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only